Book A Meeting
App Catalogue
Book A Meeting
5th Global NASH Congress
Our Team
5th Global NASH Congress

By Keen Eye - 26 Apr 2022

Keen Eye is sponsoring the 5th Global NASH Congress held on May 26th - 27th 2022 in London!
Keen Eye: better the selection of lung cancer patients to give appropriate treatments
Technology
Keen Eye: better the selection of lung cancer patients to give appropriate treatments

By Keen Eye - 18 Mar 2022

Keen Eye is laureate of the innovation contest “Concours i-Nov” in the Health theme “diagnosis, screening and surveillance of pathologies”, organized by the French Government and Bpifrance.
Optimising Quality Control in clinical trials by automating quality tissue assessment
Deep Learning
Optimising Quality Control in clinical trials by automating quality tissue assessment

By David Wallis, Thomas Le Meur - 01 Mar 2022

Drug development is a long and arduous process, with much effort expended, often for little reward. It is imperative to optimise each step of the process and create solutions that maximise the chances of success for the patient. During the tissue analysis workflow, the Quality Control (QC) assessment is crucial to the production of high quality data for a robust, quantitative and streamlined analysis. Today, this step is manually performed and qualitative, with no simple and reliable solution to identify which tissue samples can be processed for further investigation.
Propelling Pharma on the Computational Pathology Revolution
Computational Pathology
Propelling Pharma on the Computational Pathology Revolution

By Sylvain Berlemont, PhD, Founder and CEO - 08 Nov 2021

In this interview, Sylvain Berlemont, founder and CEO of Keen Eye, shares his vision on Computational Pathology.
An interview with our Quality Assurance and Regulatory Affairs Manager: what Quality means at Keen Eye
Quality
An interview with our Quality Assurance and Regulatory Affairs Manager: what Quality means at Keen Eye

By Charlotte Plestant (Scientific Content Manager), Shanyate Simonin (QARA Manager) - 31 Aug 2021

Life Science industry is among the most heavily regulated industries in the world. This regulatory environment is continuously changing in response to the introduction of new technologies, the increasing complexity of disease targets and the rising demands of both patients and regulators. We caught up with our QARA Manager Shanyate Simonin to discuss how Keen Eye deploys innovative deep learning technology within such a regulated industry.
Computer-aided diagnosis tool for cervical cancer screening with weakly supervised localization and detection of abnormalities using adaptable and explainable classifier
Deep Learning
Computer-aided diagnosis tool for cervical cancer screening with weakly supervised localization and detection of abnormalities using adaptable and explainable classifier

10 Aug 2021

Cervical cancer is the second most important cancer for women worldwide. The method uses deep convolutional neural networks. The method avoids medically critical mistakes using regression constraint in the loss term. The method uses interpretability to perform weakly supervised localisation. The method is integrated in a workflow that matches pathologist workflow. The method proposes to aggregate tile-level predictions to output a slide-level diagnosis.
Understanding spatial biology to unravel personalized medicine: Multiplex Immunofluorescence IHC combined to Deep Learning is leading the way
DEEP LEARNING
Understanding spatial biology to unravel personalized medicine: Multiplex Immunofluorescence IHC combined to Deep Learning is leading the way

By Charlotte Plestant, Louis Jeay, Suliman Bouizaguen, David Guet - 26 Jul 2021

Delivering the right treatment to the right patient, and at the right time. This motto has become the driving force in drug development, placing solutions empowering personalized medicine as a top priority in the Pathology field. The scientific community is striving to answer the technological needs required by such a challenge. Multiplex fluorescence IHC (immunohistochemistry) is a revolutionary method offering powerful possibilities in simultaneous analysis of multiple biomarkers on whole tissue sections. In this post, we describe why understanding spatial biology, the study of tissues in their 2D and 3D context, is the next big step the field has to take and how Deep Learning will assist in unraveling personalized medicine.
Computational Pathology and Artificial Intelligence are reshaping the Pathology field: an interview with Keen Eye’s Application Specialist
Our Team
Computational Pathology and Artificial Intelligence are reshaping the Pathology field: an interview with Keen Eye’s Application Specialist

By Charlotte Plestant (Scientific Content Marketing Manager), Eunice Stennett (Former CMO), David Guet (Digital pathology Specialist) - 26 May 2021

Over the last years, the world of Pathology has considerably evolved and brought out new challenges. Development of whole-slide scanners alongside Artificial Intelligence (AI) has empowered pathological analysis by digitizing immunohistochemistry, immunocytochemistry and H&E slides, providing better possibilities in patient selection and treatment. These changes have come with new hurdles, related to a sharp increase of the complexity of the images, higher expectations for image analysis and a shift in the pathologist's daily practices.
AACR Annual Meeting 2021
Our Team
AACR Annual Meeting 2021

By Paul Klein (Data Scientist), Thomas Le Meur (Data Scientist) - 08 Apr 2021

Keen Eye is presenting a scientific poster on April 10th-15th. Learn how we design deep learning workflows to quantify the H-Score on immunohistochemistry images!
Meet2Win
Our Team
Meet2Win

By Shazia Osman (Senior BD) - 08 Apr 2021

Keen Eye is attending Meet2Win on May 6th and 7th! Connect with Keen Eye to discuss how we can help you propel computational pathology to the next level for better #drugdevelopment.
Load More
10 of 35